Fate Therapeutics
FATE
39 hedge funds and large institutions have $23.9M invested in Fate Therapeutics in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 13 reducing their positions, and 10 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
15% less funds holding
Funds holding: 46 → 39 (-7)
16% less capital invested
Capital invested by funds: $28.4M → $23.9M (-$4.47M)
31% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 13
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$40.1K |
| 2 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$37.9K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$28.5K |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$27.6K |
| 5 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$12.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$1.25M |
| 2 |
Principal Financial Group
Des Moines,
Iowa
|
-$529K |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$325K |
| 4 |
Goldman Sachs
New York
|
-$250K |
| 5 |
BGA
Belmont Global Advisors
Dallas,
Texas
|
-$149K |
FATE Hedge Fund Activity: Q2 2016 in Review
39 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q2 2016, worth a combined $23.9M — down 16% from $28.4M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of FATE and 4 opened new positions — a net loss of 6 holders — while 13 trimmed existing stakes and 9 added.
The largest buyer was Vanguard Group, adding an estimated $40.1K. The largest seller was OrbiMed, exiting entirely with an estimated $1.25M sold.
- 39 institutional investors held Fate Therapeutics (FATE) as of Q2 2016, down from 46 in Q1 2016.
- Funds reported $23.9M of Fate Therapeutics stock for Q2 2016, down 16% quarter-over-quarter.
- 4 funds opened new Fate Therapeutics positions in Q2 2016 and 10 closed out, a net change of -6 holders.
- The largest Fate Therapeutics buyer in Q2 2016 was Vanguard Group, an estimated $40.1K added.
- The largest Fate Therapeutics seller in Q2 2016 was OrbiMed, an estimated $1.25M sold.
Based on aggregated 13F filings for Q2 2016.